Kailera Therapeutics Raises $600 million Series B
Kailera Therapeutics has raised $600M in Series B funding led by Foresite Capital, with participation from Foresite Capital, General Atlantic. Advance KAI-9531 clinical trials for obesity. The funds will be used to Advance KAI-9531 clinical trials for obesity.
Series B$600 millionTotal tracked $600 millionSan Diego, CA
What it does
Advance KAI-9531 clinical trials for obesity.
Traction
Kailera Therapeutics is continuing to scale after securing $600M in Series B funding led by Foresite Capital, with participation from Foresite Capital, General Atlantic.
Trend impact
Advance KAI-9531 clinical trials for obesity. As adoption in Healthcare & Life Sciences expands, focused products from Kailera Therapeutics can pressure incumbents or broader platforms that do not address the same problem directly.
Funding history
- October 1, 2025 · Series B · $600 million · Foresite Capital
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round